Vertex Pharmaceuticals (VRTX)’ povetacicept, a treatment for myasthenia gravis, was granted FDA orphan designation, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Is VRTX a Buy, Before Earnings?
- Vertex Pharmaceuticals, WuXi Biologics enter license and research service pact
- Vertex Pharmaceuticals: Positive Risk-Reward on Emerging Renal Pipeline and Pove IgAN Phase 3 Catalyst Supports Buy Rating
- Vertex Pharmaceuticals assumed with Overweight from Equal Weight at Barclays
- Vertex Pharmaceuticals price target raised to $545 from $535 at UBS